GWN Securities’s Neuropace NPCE Stock Holding History

GWN Securities’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$405K	Buy	25,470 +2,826	+12%	+$45.5K	0.07%	333
2026 Q1	$298K	Buy	+22,644	New	+$340K	0.06%	366

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

GWN Securities's NPCE Position: Q2 2026 in Review

GWN Securities increased its Neuropace (NPCE) stake by 12% in Q2 2026, buying an estimated $45.5K and bringing the position to 25,470 shares worth $405K. The position accounts for 0.07% of the portfolio, ranked #333.

GWN Securities first reported a position in NPCE in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

GWN Securities held 25,470 shares of Neuropace worth $405K as of Q2 2026.
GWN Securities bought 2,826 Neuropace shares in Q2 2026, an estimated $45.5K.
Neuropace made up 0.07% of GWN Securities's portfolio in Q2 2026, its #333 holding.
GWN Securities first reported a position in Neuropace in Q1 2026 and has held it in 2 quarters since.
113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on GWN Securities's 13F filing for Q2 2026, filed 5 Aug 2026.